Evofem Biosciences, Inc. (EVFM)
OTCMKTS: EVFM · Delayed Price · USD
0.0105
+0.0005 (5.00%)
Jul 19, 2024, 3:59 PM EDT - Market closed
Evofem Biosciences Employees
As of December 31, 2023, Evofem Biosciences had 38 total employees, including 37 full-time and 1 part-time employees. The number of employees increased by 1 or 2.70% compared to the previous year.
Employees
38
Change (1Y)
1
Growth (1Y)
2.70%
Revenue / Employee
$421,368
Profits / Employee
$1,329,579
Market Cap
651.63K
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher | 122,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
| Danaher | 63,000 |
EVFM News
- 7 days ago - Lupin Divests U.S. Commercial Women's Health Specialty Business to Evofem, including SOLOSEC - PRNewsWire
- 25 days ago - Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare - PRNewsWire
- 5 weeks ago - Evofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of Matter - PRNewsWire
- 2 months ago - Evofem Biosciences Announces Financial Results for the First Quarter of 2024 - PRNewsWire
- 3 months ago - Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO - PRNewsWire
- 4 months ago - Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 - PRNewsWire
- 4 months ago - For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy - PRNewsWire
- 6 months ago - Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023 - PRNewsWire